Regulatory Approval (ANDA)
Caplin Steriles Receives USFDA Approval for Calcium Gluconate Injection
NSE
caplinpoint
BSE
524742
Caplin Point Laboratories’ subsidiary, Caplin Steriles, has received final USFDA approval for Calcium Gluconate Injection (USP). The product targets the US injectable market with estimated annual sales of approximately $71 million.
PRICE-SENSITIVE TRIGGER
Event: USFDA Final Approval for ANDA Product
Type: Regulatory Approval (ANDA)
Impact: Positive
Immediate Effect: Strengthens Caplin’s US injectable portfolio and open incremental revenue opportunities in a niche therapeutic segment
Key Metrics:
- Market Size: ~$71 million (IQVIA, 12 months ending March 2026)
Highlight:
- Entry into a ~$71 million US injectable market with final USFDA approval
What Happened ?
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited, received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Calcium Gluconate Injection USP (100 mg/mL in 10 mL, 50 mL, and 100 mL vials).
key highlights
Product & Regulatory Details:
- Product: Calcium Gluconate Injection USP (100 mg/mL)
- Dosage forms: 10 mL, 50 mL, and 100 mL vials
- Approved under ANDA pathway
- Therapeutic use: Treatment of acute symptomatic hypocalcemia
- Generic equivalent to reference drug by Fresenius Kabi USA
- Developed and filed by Caplin Steriles
Note:
- The approval strengthens Caplin’s positioning in sterile injectables, a high-margin segment
Risk Analysis
Key Risks
- Competition from other generic injectable players
- Pricing pressure in US generics market
- Regulatory compliance and manufacturing scale-up risks
- Market penetration challenges in a niche segment
Worst Case Scenario
- If pricing pressure intensifies or competition increases, expected revenue contribution may be limited
Risk Level: Medium
Company Commentary
- Final USFDA approval received for ANDA
- Product is a generic equivalent to Fresenius Kabi’s drug
- Addresses acute hypocalcemia treatment
- Strengthens US injectable portfolio
- Approval received through subsidiary Caplin Steriles
Official Exchange Filing: Caplin Point Laboratories Limited